Cytoreductive Surgery — Tumour Debulking Procedure

Cytoreductive surgery is an extensive operative intervention deployed when a malignancy has disseminated throughout a body cavity, most commonly the peritoneal space. The primary surgical objective is optimal cytoreduction—reducing residual tumour deposits to microscopic levels or nodules smaller than one centimetre. This is achieved by resecting affected organs, peritoneal linings, and visible tumour implants.

By physically removing the bulk of poorly vascularised and hypoxic tumour tissue, cytoreductive surgery enhances the effectiveness of subsequent or intraoperative therapies. The procedure alters tumour biology by shifting remaining microscopic cancer cells into active division cycles, rendering them significantly more susceptible to systemic chemotherapy or heated intraperitoneal chemotherapy (HIPEC).

This procedure can significantly extend progression-free and overall survival for select patients with advanced cancers. Large tumour masses often have poor blood flow, which prevents chemotherapy drugs from reaching the interior cells. Removing large tumours relieves severe symptoms such as bowel blockages, fluid accumulation (ascites), and abdominal pain, while giving subsequent systemic therapies a much higher chance of controlling the remaining microscopic disease.

Before cytoreduction, patients undergo comprehensive staging through contrast-enhanced CT, MRI, or PET scans. The Peritoneal Cancer Index (PCI) is used radiographically and intraoperatively to score the extent of disease. Diagnostic laparoscopy is often performed beforehand to assess tumour resectability and ensure the patient will benefit from such an extensive operation.

Cytoreductive surgery is central to managing advanced epithelial ovarian, fallopian tube, and primary peritoneal cancers. It is also utilised for peritoneal carcinomatosis originating from appendiceal cancer, colorectal cancer, gastric cancer, and malignant peritoneal mesothelioma, often alongside heated intraperitoneal chemotherapy.

Cytoreduction is rarely used in isolation; it is a foundational component of multimodal management. In ovarian cancer, it is integrated with platinum-based intravenous chemotherapy. In gastrointestinal and appendiceal malignancies, it is frequently combined with Hyperthermic Intraperitoneal Chemotherapy (HIPEC), delivering heated cytotoxic agents directly into the abdominal cavity immediately following surgical resection.